# Exagen Inc.: overview XGN · Nasdaq · CIK 1274737 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/xgn.md) · [Financials](/companies/xgn/financials.md) · [Filings](/companies/xgn/filings.md) · [Insiders](/companies/xgn/insiders.md) Latest reported revenue: [$19.9m](/filings/0001274737-26-000048.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001274737-26-000048). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [12.5](/filings/0001274737-25-000071.md) | [13.7 d](/filings/0001274737-26-000009.md) | [15.5](/filings/0001274737-26-000029.md) | [17.2](/filings/0001274737-26-000048.md) | [17.2](/filings/0001274737-25-000071.md) | [16.6 d](/filings/0001274737-26-000009.md) | [17.3](/filings/0001274737-26-000029.md) | [19.9](/filings/0001274737-26-000048.md) | | Gross margin | % | [55.8%](/filings/0001274737-25-000071.md) | [62.1% d](/filings/0001274737-26-000009.md) | [58.9%](/filings/0001274737-26-000029.md) | [60.4%](/filings/0001274737-26-000048.md) | [58.4%](/filings/0001274737-25-000071.md) | [55.4% d](/filings/0001274737-26-000009.md) | [59.0%](/filings/0001274737-26-000029.md) | [61.3%](/filings/0001274737-26-000048.md) | | Operating margin | % | [(37.3%)](/filings/0001274737-25-000071.md) | [(24.8%) d](/filings/0001274737-26-000009.md) | [(21.7%)](/filings/0001274737-26-000029.md) | [(15.3%)](/filings/0001274737-26-000048.md) | [(18.0%)](/filings/0001274737-25-000071.md) | [(29.9%) d](/filings/0001274737-26-000009.md) | [(19.7%)](/filings/0001274737-26-000029.md) | [(8.6%)](/filings/0001274737-26-000048.md) | | Net margin | % | [(40.2%)](/filings/0001274737-25-000071.md) | [(27.5%) d](/filings/0001274737-26-000009.md) | [(24.2%)](/filings/0001274737-26-000048.md) | [(25.8%)](/filings/0001274737-26-000048.md) | [(41.1%)](/filings/0001274737-25-000071.md) | [(28.1%) d](/filings/0001274737-26-000009.md) | [(22.9%)](/filings/0001274737-26-000048.md) | [(16.0%)](/filings/0001274737-26-000048.md) | | Diluted EPS | $ per share | [(0.28)](/filings/0001274737-25-000071.md) | not reported | [(0.20)](/filings/0001274737-26-000029.md) | [(0.21)](/filings/0001274737-26-000048.md) | [(0.31)](/filings/0001274737-25-000071.md) | not reported | [(0.17)](/filings/0001274737-26-000029.md) | [(0.13)](/filings/0001274737-26-000048.md) | | Free cash flow | $m | [(2.3) d](/filings/0001274737-25-000071.md) | [0.2 d](/filings/0001274737-26-000009.md) | [(10.8)](/filings/0001274737-26-000029.md) | [(3.1) d](/filings/0001274737-26-000048.md) | [2.7 d](/filings/0001274737-25-000071.md) | [(3.1) d](/filings/0001274737-26-000009.md) | [(10.6)](/filings/0001274737-26-000029.md) | [3.4 d](/filings/0001274737-26-000048.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [48.3](/filings/0001274737-23-000019.md) | [45.6](/filings/0001274737-24-000022.md) | [52.5](/filings/0001274737-25-000019.md) | [55.6](/filings/0001274737-26-000009.md) | [66.6](/filings/0001274737-26-000009.md) | | Gross margin | % | not reported | not reported | [56.1%](/filings/0001274737-25-000019.md) | [59.5%](/filings/0001274737-26-000009.md) | [58.3%](/filings/0001274737-26-000009.md) | | Operating margin | % | [(49.8%)](/filings/0001274737-23-000019.md) | [(101.1%)](/filings/0001274737-24-000022.md) | [(43.5%)](/filings/0001274737-25-000019.md) | [(24.5%)](/filings/0001274737-26-000009.md) | [(21.1%)](/filings/0001274737-26-000009.md) | | Net margin | % | [(55.6%)](/filings/0001274737-23-000019.md) | [(104.0%)](/filings/0001274737-24-000022.md) | [(45.1%)](/filings/0001274737-25-000019.md) | [(27.2%)](/filings/0001274737-26-000009.md) | [(30.0%)](/filings/0001274737-26-000009.md) | | Diluted EPS | $ per share | [(1.68)](/filings/0001274737-23-000019.md) | [(2.77)](/filings/0001274737-24-000022.md) | [(1.34)](/filings/0001274737-25-000019.md) | [(0.83)](/filings/0001274737-26-000009.md) | [(0.93)](/filings/0001274737-26-000009.md) | | Free cash flow | $m | [(22.6)](/filings/0001274737-23-000019.md) | [(36.5)](/filings/0001274737-24-000022.md) | [(15.3)](/filings/0001274737-25-000019.md) | [(13.8)](/filings/0001274737-26-000009.md) | [(14.3)](/filings/0001274737-26-000009.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Gross profit: us-gaap:GrossProfit. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/xgn/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [WEXFORD CAPITAL LP](/funds/1048462.md) | 2026-06-30 | $3.7m | 792,855 | | Unchanged | | [NANO CAP NEW MILLENNIUM GROWTH FUND L P](/funds/1277890.md) | 2026-06-30 | $3.1m | 675,000 | | Added +90,000 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.8m | 612,832 | | Reduced −65,820 | | [FourWorld Capital Management LLC](/funds/1770525.md) | 2026-06-30 | $2.8m | 596,528 | | Added +156,578 | | [SILVERCREST ASSET MANAGEMENT GROUP LLC](/funds/1232395.md) | 2026-06-30 | $2.4m | 514,761 | | Reduced −23,109 | | [KENNEDY CAPITAL MANAGEMENT LLC](/funds/884589.md) | 2026-06-30 | $2.3m | 485,048 | | Reduced −8,612 | | [Mink Brook Asset Management LLC](/funds/2052205.md) | 2026-06-30 | $2.2m | 475,944 | | Added +106,917 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $1.5m | 322,502 | | Added +85,767 | | [First Eagle Investment Management, LLC](/funds/1325447.md) | 2026-06-30 | $1.4m | 306,965 | | Added +181,723 | | [First Eagle Investment Management, LLC](/funds/1325447.md) | 2026-06-30 | $1.4m | 306,965 | | Added +181,723 | ## Recent filings [All 412 filings](/companies/xgn/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-04 | 13:15 ET | [10-Q](/filings/0001274737-26-000048.md) | Quarterly report, period 2026-06-30 | 0001274737-26-000048 | | 2026-08-04 | 12:02 ET | [8-K](/filings/0001274737-26-000047.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001274737-26-000047 | | 2026-06-09 | 20:14 ET | [8-K](/filings/0001274737-26-000033.md) | 5.07 Shareholder vote results | 0001274737-26-000033 | | 2026-05-11 | 13:17 ET | [10-Q](/filings/0001274737-26-000029.md) | Quarterly report, period 2026-03-31 | 0001274737-26-000029 | | 2026-05-11 | 12:03 ET | [8-K](/filings/0001274737-26-000027.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001274737-26-000027 | | 2026-04-27 | 21:17 ET | [DEF 14A](/filings/0001274737-26-000020.md) | Proxy statement, period 2026-06-09 | 0001274737-26-000020 | | 2026-04-23 | 20:02 ET | [8-K](/filings/0001274737-26-000015.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001274737-26-000015 | | 2026-03-10 | 13:22 ET | [10-K](/filings/0001274737-26-000009.md) | Annual report, period 2025-12-31 | 0001274737-26-000009 | | 2026-03-10 | 12:03 ET | [8-K](/filings/0001274737-26-000007.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001274737-26-000007 | | 2026-01-12 | 14:03 ET | [8-K](/filings/0001274737-26-000003.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001274737-26-000003 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001274737-26-000009.md), filed Mar 10, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/36ee0b26-ce12-425f-84b8-b0665142e32d) ## About the filer - CIK: 1274737 - Tickers: XGN - Exchange: Nasdaq - SIC code: 8071 Services-Medical Laboratories - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.